Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Sumitovant Biopharma Helps Identify More Than 80 Peptide Drug Candidates for Neochromosome’s Differentiated Manufacturing Technology

Sumitovant Biopharma, a technology-driven biopharmaceutical company accelerating the development and commercialization of novel therapeutics, announced it has identified more than 80 peptide drug candidates for manufacturing, using the company’s DrugOME computational platform. As part of a collaboration with Neochromosome, Inc. (“Neochromosome”), Sumitovant used extensive natural language processing (NLP) to systematically explore libraries of traditional and non-traditional data sources. The identified protein candidates enable Neochromosome to pursue actionable opportunities for its genome-scale engineering technology and its neoYeast protein discovery and manufacturing platform.

Recommended AI News: OmniML Secures $10 Million to Accelerate AI Computing on Edge Devices

“This partnership with Neochromosome is a great example of how we can pair our proprietary artificial intelligence and natural language processing platform DrugOME to accelerate many aspects of scientific research and competitive intelligence,” said Bill McMahon, chief algorithmic analytics officer at Sumitovant. “Sumitovant’s extensive life-sciences expertise, combined with our in-house technology platforms, provide a unique opportunity for our portfolio assets as well as external partners to accelerate the drug discovery, development, and commercialization processes.”

Sumitovant’s novel technologies allowed Neochromosome to quickly identify the compounds composed of non-canonical amino acids with chemistries not found in nature. Using DrugOME, the collaborators dramatically reduced time and cost, ultimately transforming stakeholder needs into usable information for the development of safer, more effective therapeutics.

Related Posts
1 of 33,960

“Our collaboration with Sumitovant expedited a typically risky and lengthy process, emphasizing how much more we achieved by leveraging the technologies that Sumitovant has developed and refined in-house over years,” said Leslie Mitchell, co-founder and CEO of Neochromosome. “This collaboration enabled us to identify promising peptide drug candidates for neoYeast including those that have the potential to positively impact unmet medical needs. We achieved results that would not have been possible under normal timelines.”

Recommended AI News: Fastly Acquires Fanout to Unlock Real-Time App Development at the Edge

DrugOME is Sumitovant’s computational ecosystem, enabling strategic analyses to inform the complete picture of a treatment’s potential, identifying early discovery targets, a drug’s mechanism of action, clinical risks and costs, and selecting an indication – from clinical strategy to development and execution of commercial efforts. By utilizing this platform, alongside Sumitovant’s technologists and team of life-sciences experts, Sumitovant has developed a novel approach to drug discovery and development – from research through commercialization.

Recommended AI News: CommScope Propels Data Centers into the Future

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.